Novo Nordisk A/S (NYSE:NVO) Short Interest Down 14.9% in February

Novo Nordisk A/S (NYSE:NVO) was the target of a large decline in short interest during the month of February. As of February 13th, there was short interest totaling 26,973,270 shares, a decline of 14.9% from the January 29th total of 31,693,294 shares. Approximately 0.6% of the shares of the stock are sold short. Based on an average trading volume of 30,479,797 shares, the short-interest ratio is presently 0.9 days. Based on an average trading volume of 30,479,797 shares, the short-interest ratio is presently 0.9 days. Approximately 0.6% of the shares of the stock are sold short.

Novo Nordisk A/S Trading Up 5.0%

Shares of NVO stock traded up $1.84 during mid-day trading on Wednesday, hitting $38.50. The company’s stock had a trading volume of 23,051,653 shares, compared to its average volume of 26,902,344. The company has a market cap of $171.90 billion, a PE ratio of 11.10 and a beta of 0.73. The company has a debt-to-equity ratio of 0.61, a quick ratio of 0.57 and a current ratio of 0.80. The company’s fifty day simple moving average is $52.24 and its 200-day simple moving average is $52.68. Novo Nordisk A/S has a 52 week low of $35.85 and a 52 week high of $91.90.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share for the quarter, topping analysts’ consensus estimates of $0.90 by $0.11. The business had revenue of $12.43 billion during the quarter, compared to the consensus estimate of $11.97 billion. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%. As a group, equities research analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Dividend Announcement

The business also recently declared a dividend, which will be paid on Wednesday, April 8th. Shareholders of record on Monday, March 30th will be paid a $1.2751 dividend. This represents a yield of 541.0%. The ex-dividend date of this dividend is Monday, March 30th. Novo Nordisk A/S’s payout ratio is 23.63%.

Analyst Ratings Changes

A number of analysts have recently commented on the company. Deutsche Bank Aktiengesellschaft lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Monday, February 23rd. BMO Capital Markets reissued a “market perform” rating on shares of Novo Nordisk A/S in a report on Thursday, February 5th. Jefferies Financial Group raised shares of Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a research note on Thursday, February 12th. Argus reissued a “hold” rating on shares of Novo Nordisk A/S in a research note on Monday, December 8th. Finally, Weiss Ratings raised Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, February 5th. Five research analysts have rated the stock with a Buy rating, seventeen have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $53.93.

Institutional Trading of Novo Nordisk A/S

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Franklin Resources Inc. lifted its holdings in shares of Novo Nordisk A/S by 4,190.8% in the 3rd quarter. Franklin Resources Inc. now owns 13,984,789 shares of the company’s stock worth $776,016,000 after purchasing an additional 13,658,867 shares in the last quarter. Capital International Investors lifted its stake in shares of Novo Nordisk A/S by 52.4% in the third quarter. Capital International Investors now owns 17,713,424 shares of the company’s stock valued at $982,969,000 after buying an additional 6,092,192 shares in the last quarter. Boston Partners bought a new position in shares of Novo Nordisk A/S in the third quarter valued at $310,199,000. Price T Rowe Associates Inc. MD grew its holdings in shares of Novo Nordisk A/S by 99.7% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 9,688,262 shares of the company’s stock valued at $492,940,000 after buying an additional 4,836,285 shares during the last quarter. Finally, Voloridge Investment Management LLC increased its position in shares of Novo Nordisk A/S by 851.6% during the fourth quarter. Voloridge Investment Management LLC now owns 4,807,279 shares of the company’s stock worth $244,594,000 after acquiring an additional 4,302,126 shares in the last quarter. 11.54% of the stock is owned by institutional investors.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Morgan Stanley upgraded NVO to Equal-weight, saying the recent sell-off better prices mid‑term risks and setting a $40 price target — this reduced perceived downside and likely helped buying interest. Morgan Stanley upgrades Novo Nordisk, says risks better priced after sell-off
• Positive Sentiment: Investors reacted to FDA moves against telehealth GLP‑1 advertisers as potentially removing low‑quality/rogue competition and stabilizing branded channel economics for incumbents like Novo. Novo Nordisk (NVO) Stock Jumps 3% as FDA Cracks Down on Telehealth GLP-1 Advertisers
• Positive Sentiment: Company is investing heavily in production capacity (Ireland facility upgrades and a Monksland expansion) to secure supply for Wegovy and oral formulations — positive for long‑term market defense. Novo Nordisk Announces $372.5M Expansion in Monksland, Athlone, Ireland
• Neutral Sentiment: Market debate on valuation and whether current pricing reflects too much pessimism continues; some pieces argue downside is priced while others flag remaining execution/competitive risks. Is Novo Nordisk (NYSE:NVO) Now Pricing In Too Much Pessimism After Share Price Slump
• Neutral Sentiment: Roche and other rivals are explicitly targeting the obesity market — a longer‑term competitive factor investors are watching but not an immediate earnings shock. Roche targets double-digit market share in weight loss, aims to catch up with Novo
• Negative Sentiment: The FDA issued a second warning ordering Novo to stop a consumer Ozempic ad for being misleading — immediate regulatory/marketing headwind and reputational risk. US FDA warns Novo for second time about misleading Ozempic advertising
• Negative Sentiment: Pomerantz has opened an investor investigation into Novo — potential litigation risk that can weigh on sentiment if it escalates. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/S – NVO
• Negative Sentiment: Planned halving of Wegovy’s US list price in 2027 signals pricing pressure and margin risk for the obesity franchise (volume vs. price trade‑off). Novo Nordisk to halve US list price of Wegovy in 2027
• Negative Sentiment: The American Hospital Association urged HRSA to stop Novo’s new claims‑data submission policy affecting 340B hospitals, adding regulatory and stakeholder friction. AHA urges HRSA to stop Novo Nordisk’s new claims-data submission policy on 340B hospitals from going into effect
• Negative Sentiment: Generic/biosimilar Ozempic competition is progressing (Canada generic anticipated), a potential revenue headwind in affected markets. Aspen expects Canada nod for generic targeting Novo’s Ozempic by September

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.